Do Analysts Think Aclaris Therapeutics Inc (ACRS) Is Still Worth Buying In 2024?

Aclaris Therapeutics Inc (NASDAQ:ACRS) does about 838.43K shares in volume on a normal day but saw 1364896 shares change hands in Monday trading. The company now has a market cap of 90.50M USD. Its current market price is $1.27, marking an increase of 5.83% compared to the previous close of $1.20. The 52 week high reached by this stock is $11.12 whilst the lowest price level in 52 weeks is $0.59.

Aclaris Therapeutics Inc (ACRS) has a 20-day trading average at $1.1532 and the current price is -88.58% off the 52-week high compared with 115.18% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.1614 and its 200-day simple moving average is $1.9929. If we look at the stock’s price movements over the week, volatility stands at 8.77%, which decreases to 7.95% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 61.43 to suggest the stock is neutral.

The consensus objective for the share price is $1.84, suggesting that the stock has a potential upside of 30.98% over the period.

Evercore ISI initiated its price target at $22.

Aclaris Therapeutics Inc (ACRS) stock is up 15.45% over the week and 20.95% over the past month. Its price is 20.95% year-to-date and -87.56% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of -0.42 above consensus estimates by 0.03. The company’s next earnings report forecasts estimating quarterly EPS at -0.2 and -0.8 for whole year. Expected sales for next quarter are $1.83M, which analysts say will come at $7.89M for the current fiscal year and next year at $7.74M. In addition, estimates put the company’s current quarterly revenue at an average of $1.82M.

To reach the target analysts have set, the stock logically needs to grow 30.98 percent from here.

Outstanding shares total 70.89M with insiders holding 2.55% of the shares and institutional holders owning 78.02% of the company’s common stock. The company has a return on investment of -53.29% and return on equity of -48.47%. The beta has a value of 0.28. Price to book ratio is 0.64 and price to sales ratio is 2.91.